Continuous renal replacement therapy: Does technique influence azotemic control?

被引:7
作者
Morimatsu, H [1 ]
Uchino, S [1 ]
Bellomo, R [1 ]
Ronco, C [1 ]
机构
[1] Austin & Repatriat Med Ctr, Dept Intens Care, Melbourne, Vic 3084, Australia
关键词
hemofiltration; hemodialysis; acute renal failure; urea; creatinine; uremia; critical illness;
D O I
10.1081/JDI-120013969
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Different techniques of continuous renal replacement therapy (CRRT) might have different effects on azotemic control. Accordingly, we tested whether continuous veno-venous hemodiafiltration (CVVHDF) or continuous veno-venous hemofiltration (CVVH) would achieve better control of serum creatinine and plasma urea levels. Design: Retrospective controlled study. Setting: Two tertiary Intensive Care Units. Patients: Critically ill patients with acute renal failure (ARF) treated with CVVHDF (n = 49) or CVVH (n = 50). Interventions: Retrieval of daily morning urea and creatinine values before and after the initiation of CRRT for up to 2 weeks of treatment. Measurements and Results: Before treatment, serum urea and creatinine concentrations were significantly lower in the CVVH group than in CVVHDF group (urea: 31.0 +/- 15.0 mmol/L for CVVHDF and 24.7 +/- 16.1 mmol/L for CVVH, p = 0.01, creatinine: 547 +/- 308 mumol/L vs. 326 +/- 250 mumol/L, p < 0.0001). These differences were still significant after 48 h of treatment (urea: 20.1 +/- 8.3 mmol/L vs. 14.1 +/- 6.1 mmol/L; p = 0.0003, creatinine: 360 +/- 189 μmol/L vs. 215 +/- 118 μmol/L; p < 0.0001). Throughout the duration of therapy, mean urea levels (22.3 +/- 9.0 mmol/L for CVVHDF vs. 16.7 +/- 7.8 mmol/L for CVVH, p < 0.0001) and mean creatinine levels (302 +/- 167 vs. 211 +/- 103 μmol/L, p < 0.0001) were better controlled in the CVVH group. Conclusions: CRRT strategies based on different techniques might have a significantly different impact on azotemic control.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 15 条
[1]  
Bellomo R, 1996, NEPHROL DIAL TRANSPL, V11, P424
[2]   Continuous haemofiltration in the intensive care unit [J].
Bellomo, R ;
Ronco, C .
CRITICAL CARE, 2000, 4 (06) :339-345
[3]   Acute renal failure in intensive care units - Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study [J].
Brivet, FG ;
Kleinknecht, DJ ;
Loirat, P ;
Landais, PJM ;
Bedock, B ;
Bleichner, G ;
Richard, C ;
Coste, F ;
BrunBuisson, C ;
Sicot, C ;
Tenaillon, A ;
Gajdos, P ;
Blin, F ;
Saulnier, F ;
Agostini, MM ;
Nicolas, F ;
FeryLemonnier, E ;
Staikowski, F ;
Carlet, J ;
Guivarch, G ;
Fraisse, F ;
Ricome, J ;
Tempe, JD ;
Mezzarobba, P .
CRITICAL CARE MEDICINE, 1996, 24 (02) :192-198
[4]   Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates [J].
Brunet, S ;
Leblanc, M ;
Geadah, D ;
Parent, D ;
Courteau, S ;
Cardinal, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :486-492
[5]   CRRT efficiency and efficacy in relation to solute size [J].
Clark, WR ;
Ronco, C .
KIDNEY INTERNATIONAL, 1999, 56 :S3-S7
[6]   A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a "closed" ICU system [J].
Cole, L ;
Bellomo, R ;
Silvester, W ;
Reeves, JH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (01) :191-196
[7]   APACHE-II - A SEVERITY OF DISEASE CLASSIFICATION-SYSTEM [J].
KNAUS, WA ;
DRAPER, EA ;
WAGNER, DP ;
ZIMMERMAN, JE .
CRITICAL CARE MEDICINE, 1985, 13 (10) :818-829
[8]   Continuous renal replacement therapies: An update [J].
Manns, M ;
Sigler, MH ;
Teehan, BP .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (02) :185-207
[9]   Establishing a dialysis therapy patient outcome link in intensive care unit acute dialysis for patients with acute renal failure [J].
Paganini, EP ;
Tapolyai, M ;
Goormastic, M ;
Halstenberg, W ;
Kozlowski, L ;
Leblanc, M ;
Lee, JC ;
Moreno, L ;
Sakai, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (05) :S81-S89
[10]  
RONCO C, 1993, CLIN NEPHROL, V40, P187